Validation of the CRAFITY score in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab
Journal of Hepatology(2023)
Abstract
Background We recently developed the CRP and AFP in Immunotherapy (CRAFITY) score in patients with HCC undergoing immune checkpoint inhibitor (ICI) therapy. As CRAFITY was developed in patients undergoing different ICI-based regimens, the score requires validation in patients treated with atezolizumab and bevacizumab (AB).
MoreTranslated text
Key words
hepatocellular carcinoma,atezolizumab,bevacizumab,crafity score
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined